October 26, 2020

Austin, Texas – CReDO Science (https://credo-science.com) is proud to announce the launch of a formulation service for therapeutic cannabis-based products. This would include the crafting of unique and customized supplements for over-the-counter sales, and provision of formulations for pharmaceutical development and regulatory approval by the US Food and Drug Administration (FDA), Health Canada (HC), and European Medicines Agency (EMA).

CReDO Science, CEO, cannabis research and drug development pioneer Dr. Ethan Russo says, “Our aim is to provide blueprints for synergistic preparations of cannabis extracts and components that leverage the entourage effect of the many therapeutic compounds in cannabis. Only then can the full potential of cannabis be realized to provide medicines that are safe, effective and consistent.” 

Dr. Russo is a board-certified neurologist and the author/co-author of over 50 peer-reviewed journal articles and seven books on medical cannabis and the endocannabinoid system. A veteran of GW Pharmaceuticals, Dr. Ethan Russo served as the Medical Monitor and Study Physician for the clinical trials of Sativex® and Epidiolex®, the first cannabis-based pharmaceuticals to market.

A pioneer in the area of medical cannabis research and drug development, Dr. Russo understands deeply the intricacies of formulating botanical medicines and the regulatory approval pathways and requirements. As one of the few people in the world who has helped secure FDA approval for a cannabis plant-based pharmaceutical, he has participated in over 20 clinical trials for cannabis-based pharmaceuticals designed for treatment of amyotrophic lateral sclerosis, multiple sclerosis, neuropathic pain, cancer pain, autism, and epilepsy.

“Due to a variety of factors including prohibition and political barriers to research, the available literature on therapeutic applications of cannabis has frequently resulted in mixed or negative results that can be attributed to utilization of unstandardized material without consideration to its biochemical composition. It rarely has been the case that randomized controlled trials, the gold standard of medical proof of safety and efficacy, have been undertaken with truly optimized cannabis formulations,” laments Dr. Russo. CReDO Science wants to change that.

Companies will find that Dr. Russo’s expertise will provide considerable cost savings by significantly reducing product development timelines and increasing product value by creating more competitive products. Such a formulation service is necessary to achieve CReDO Science’s mission of “Making Cannabis Safer and Better.”

Click here to download the pdf version of the press release.

Contact: Nishi Whiteley, nw at credo-science dot com

Austin, Texas, March 30, 2020 – Ethan Russo, MD, Founder/CEO and Nishi Whiteley, Co-founder/COO are pleased to announce the launch of CReDO Science, LLC (https://credo-science.com) a company devoted to research and development of disruptive technologies affecting the endocannabinoid system (ECS), the major homeostatic regulatory system of human and animal physiology.

Dr. Russo has almost 25 years’ experience in the ECS and cannabis research space including his high-profile work as Senior Medical Advisor at GW Pharmaceuticals and the Medical Monitor and Study Coordinator for the Sativex® and Epidiolex® trials, the only two cannabis-derived pharmaceuticals. A thought leader in the space, he is forever being asked, “What should we be working on?” CReDO Science will focus on exactly this. Initial CReDO Science efforts will concentrate in six areas for which provisional patents are in progress: a novel extraction technique for cannabis, an overthe-counter product for a common condition for which current treatments are toxic or poorly effective, a non-cannabinoid nutritional product from cannabis with expected broad anti-inflammatory effects, an inexpensive diagnostic test for two conditions that currently lack specific tools (so-called “diagnoses of exclusion”) and a novel Corona virus-killing disinfectant.

“We are very excited to be in a position to investigate and market new products, technologies and diagnostics leveraging the endocannabinoid system that portend to contribute towards meaningful advances in medicine, health and fitness, as well as industrial applications”, says founder and CEO Dr. Russo. “CReDO Science develops products and diagnostics that should be available internationally without the jurisdictional restrictions related to controlled substances, such as THC.”

The cannabis business worldwide is experiencing explosive growth as laws change and cannabis use becomes normalized. According to Arcview’s, State of Legal Cannabis Markets Report 7th Edition, the US total cannabinoid market alone is projected to be over $44.8B by 2024. CReDO Science co-founder Nishi Whiteley says, “These figures are staggering, especially when you consider that biopharma, nutraceutical and supplement companies have barely gotten into the game. These three areas are the new frontier in the cannabis space. With revered medical cannabis expert Dr. Ethan Russo at the helm, we aspire to solve the most important issues of the human endocannabinoid system with safe, non-toxic cannabis-based solutions.”

Beyond the proprietary internal R&D program, CReDO Science will be leveraging its principals’ knowledge and experience through consultation to and collaboration with meritorious partners and programs. These include Breeder’s Best (https://breedersbest.com/), a company seeking to develop improved cannabis genetics through conventional breeding, organic and regenerative culture, and best practices, (both Russo and Whiteley maintain leadership roles at Breeder’s Best due to the symbiotic nature of the two businesses), True Terpenes (https://trueterpenes.com/), the leading innovator and producer of GMP/ISO/FSSC-certified, effects-based terpenes and terpenoids from hemp and other plants, and a Canadian company developing pharmaceuticals derived from cannabis delivered via an innovative technique to treat serious illnesses currently lacking viable alternatives.

“We will distinguish ourselves from the many other companies in the cannabis space that are largely engaged in attempts to sell similar wares with questionable degrees of quality control in what I would term a ‘race to the bottom,” says Dr. Russo. “CReDO Science intends to raise the bar to bring safer and better cannabis products into mainstream commerce for improved endocannabinoid balance.”

To learn more about CReDO Science, visit www.Credo-Science.com.

Download this press release in PDF form here.